CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Synlogic,
Inc. (Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
presented data on SYNB1891 for the treatment of solid tumors and
lymphoma during the American Association for Cancer Research (AACR)
annual meeting, April 10-15,
2021.
The presentation, "Intratumoral injection of SYNB1891, a
Synthetic Biotic designed to activate the innate immune system,
demonstrates target engagement in humans including intratumoral
STING activation," was delivered by Dr. Filip Janku, Associate Professor, Department of
Investigational Cancer Therapeutics, Division of Cancer Medicine at
The University of Texas MD Anderson
Cancer Center. The presentation recording will be available
throughout the duration of the conference.
SYNB1891 is an investigational drug being evaluated in an
ongoing Phase 1 clinical trial for the treatment of solid tumors
and lymphoma. SYNB1891 is composed of an engineered Synthetic
Biotic strain of E. coli Nissle that produces cyclic di-AMP (CDA),
a stimulator of the STING (STimulator of INterferon
Genes) pathway. This mechanism can play a critical role in the
initiation of an anti-tumor immune response via activation of APCs
and presentation of tumor antigens. Findings from the monotherapy
cohorts include:
- SYNB1891 is safe and well-tolerated as an intratumoral
injection in a heterogenous population.
-
- No dose limiting toxicities or SYNB1891-related infections
- Dose levels through 1e7 live cells demonstrate target
engagement as assessed by dose-dependent increases in serum
cytokines, upregulation of ISGs and presence of tumor infiltrating
lymphocytes.
- Evidence of durable stable disease was seen in 2 patients and
was associated with upregulation genes tied to immune activation
and increased intratumoral lymphocytes.
These data support continued dose escalation in the monotherapy
and combination arms. The combination arm of the study combines
escalating dose levels of SYNB1891 with a fixed dose of a PD-L1
checkpoint inhibitor antibody to establish a recommended Phase 2
dose for the combination regimen.
Data from both arms will continue to be reported over the course
of 2021, with mature combination therapy data expected by the end
of the year.
Learn more about Synlogic's programs and pipeline by
visiting https://www.synlogictx.com/.
About SYNB1891
SYNB1891 is an investigational drug for
the intra-tumoral treatment of solid tumors and lymphoma, composed
of an engineered Synthetic Biotic strain of E. coli Nissle that
produces cyclic di-AMP (CDA), a stimulator of
the STING (STimulator of INterferon Genes)
pathway. This mechanism can play a critical role in the
initiation of an anti-tumor immune response via activation of APCs
and presentation of tumor antigens. The bacterial chassis of
SYNB1891 also stimulates the innate immune system by several other
mechanisms, including via Toll-like receptors (TLRs), potentially
adding to the magnitude of the overall immune response. While
SYNB1891 has been engineered with safety features that are designed
to prevent its replication unless supplemented with specific
nutrients, the bacteria remain active for several days within the
injected tumor to stimulate a local immune response. SYNB1891 is
being evaluated in a Phase 1 clinical trial (NCT04167137).
About Synlogic
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic medicines that target validated underlying biology
to treat disease in new ways. Synlogic's proprietary pipeline
includes Synthetic Biotics for the treatment of metabolic disorders
including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The
company is also building a portfolio of partner-able assets in
immunology and oncology.
Forward-Looking Statements
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; our expectations about sufficiency of our
existing cash balance; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; and the
expected timing of Synlogic's clinical trials of SYNB1891 and
availability of clinical trial data. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including: the uncertainties inherent
in the clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original
content:http://www.prnewswire.com/news-releases/synlogic-presents-data-from-synb1891-phase-1-trial-at-american-association-for-cancer-research-aacr-annual-meeting-301266169.html
SOURCE Synlogic, Inc.